Synageva BioPharma (GEVA +5.1%) gets a kickstart with a timely initiation from Wedbush to...

|About: Synageva BioPharma Corp. (GEVA)|By:, SA News Editor

Synageva BioPharma (GEVA +5.1%) gets a kickstart with a timely initiation from Wedbush to Outperform with a price target of $32. Analysts see Phase I/II releases in 2012 building on positive results with the firm's treatment for Wolman disease. Shares of GEVA hit a 52-week high off the momentum.